ALIX regulates the immunosuppressive properties in basal-like breast cancer (BLBC) cells by enhancing PD-L1 sorting onto ILVs and its release into the microenvironment to deplete PD-L1 surface presentation [30]. This evidence concerns the gene CD274 and breast carcinoma.